0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Special Feature |

Picture of the Month FREE

[+] Author Affiliations

Section Editor: Walter W. Tunnessen, MD

More Author Information
Arch Pediatr Adolesc Med. 1998;152(2):204. doi:.
Text Size: A A A
Published online

DENOUEMENT AND DISCUSSION: CUTANEOUS LARVA MIGRANS (CREEPING ERUPTION)

Figure 1. Serpiginous, erythematous, raised tracks are seen on the foot of a 3-year-old child.

Figure 2. The dorsum of the left foot of an 11-year-old girl shows an irregular area of raised tracks.

Figure 3. A serpiginous, raised track is seen on the buttocks of an 18-month-old child who sat bare bottomed on a Venezuelan beach.

A pruritic lesion appeared on the buttock of an 18-month-old child who had visited Venezuela (Figure 3).

Cutaneous larva migrans, or creeping eruption, was first described in 1874. It is the most common tropically acquired dermatosis.1 The lesions are the result of cutaneous infestation and migration by third-stage larval nematodes of the cat and dog hookworms, Ancylostoma braziliensis and Ancylostoma duodenale, and occasionally other hookworms. Adult worms live and multiply in the animal's intestine and are shed during defecation. The infection is acquired by humans when they walk barefooted or crawling in sandy or shady areas, particularly around beaches and under houses. Confirmation that the affected body part was exposed to contact with sand or soil can usually be elicited by obtaining a history.2

Animal infestations with hookworms are most common in the Caribbean, South America, Southeast Asia, and the southeastern United States. A recent history of travel to a tropical or subtropical climate should be sought when one is confronted with a lesion suspected of being creeping eruption. In a report from a tropical disease unit in Toronto, Ontario, 75% of the 60 affected individuals had a history of recent travel to the Caribbean, while only 3.3% had recently visited Florida.3 Family outbreaks have been reported when household pets are infested.4

CLINICAL FINDINGS

The eruption usually begins with an inflamed papule, often between the toes. The tracks of the larvae's path through the skin are often seen within the first 2 weeks of the patient's return from a tropical environment.3 While the dorsal and plantar surfaces of the feet are most commonly affected, other areas such as the hands, buttocks, thighs, and chest may occasionally develop lesions.

On presentation there may be single or multiple serpiginous tracks that enlarge 1 to 2 cm per day.2,5 The larvae enter the skin through breaks in the surface, through hair follicles, or even through intact skin. The larvae cannot complete their life cycle in the human and are trapped in the epidermis, leaving an erythematous plaque in their path. Vesicular and bullous lesions, erosions, and folliculitis may be seen.

The lesions of cutaneous larva migrans are classic, and when combined with a supportive history of possible exposure, the picture is diagnostic. Occasionally lesions may be mistaken for fungal infections or inflammatory dermatoses.3 Pruritus is intractable and may be related to eosinophilia or elevated levels of IgE, which may be persistently abnormal up to 4 weeks after treatment of the infestation.2,6 Pain and local swelling may also be present.

TREATMENT

The treatment of choice in the United States is the cutaneous application of 10% to 15% thiabendazole cream, made by crushing a 500-mg tablet of the drug in 5 g of a water-soluble cream, or the use of oral thiabendazole suspension topically.2,7 The cream or suspension is applied to the lesion, particularly ahead of the advancing edge, 3 or 4 times a day. Oral thiabendazole at a dose of 25 to 50 mg/kg for 2 to 4 days is useful for cases resistant to topical therapy, but it is associated with many side effects, including dizziness, nausea, vomiting, and diarrhea. Alternatively, oral albendazole as a single 400-mg dose or 200 mg twice daily for 3 days may be given. While clearance of the infestation is comparable between the 2 oral regimens, single dosing is associated with a higher incidence of relapse.1,3,8 Ivermectin, recently approved for use in adults for the treatment of resistant scabies, was shown in one study to be effective in a single 12-mg dose. 9 Local destructive therapies, such as with liquid nitrogen, have not been found to be effective.1,3

Accepted for publication June 2, 1997.

Reprints: Nanette B. Silverberg, MD, Department of Dermatology, SUNY Health Science Center of Brooklyn, 450 Clarkson Ave, Box 46, Brooklyn, NY 11203.

Caumes  ECarriere  JGuermonprez  GBricaire  FDanis  MGentilini  M Dermatoses associated with travel to tropical countries: a prospective study of the diagnosis and management of 269 patients presenting to a tropical disease unit. Clin Infect Dis. 1995;20542- 548
Link to Article
Rothe  MKerdel  FAFarah  FS Cutaneous larva migrans. Demis  DJed.Clin Dermatol. 22nd rev. Philadelphia Lippincott Raven1995;18- 161- 8
Davies  HDSakuls  PKeystone  JS Creeping eruption: a review of clinical presentation and management of 60 cases presenting to a tropical disease unit. Arch Dermatol. 1993;129588- 591
Link to Article
Ogunbanjo  BOEdungbola  LD Outbreak of cutaneous larva migrans in a family household. Trop Geogr Med. 1989;4166- 68
Chaudry  AZLongworth  DL Cutaneous manifestations of intestinal helminthic infections. Dermatol Clin. 1989;7275- 290
Kahn  GJohnson  JA Serum IgE levels in cutaneous larva migrans. J Dermatol. 1971;10201- 203
Harland  PSMeakins  RHHarland  RH Treatment of cutaneous larva migrans with local thiabendazole. BMJ. 1977;2772
Link to Article
Orihuela  ARTorres  JR Single dose of albendazole in the treatment of cutaneous larva migrans. Arch Dermatol. 1990;126398- 399
Link to Article
Caumes  ECarriere  JPatry  AGaxotti  PDanis  MGentilini  M A randomized trial of ivermectin versus albendazole for the treatment of cutaneous larva migrans. Am J Trop Med Hyg. 1993;45641- 644

Tables

References

Caumes  ECarriere  JGuermonprez  GBricaire  FDanis  MGentilini  M Dermatoses associated with travel to tropical countries: a prospective study of the diagnosis and management of 269 patients presenting to a tropical disease unit. Clin Infect Dis. 1995;20542- 548
Link to Article
Rothe  MKerdel  FAFarah  FS Cutaneous larva migrans. Demis  DJed.Clin Dermatol. 22nd rev. Philadelphia Lippincott Raven1995;18- 161- 8
Davies  HDSakuls  PKeystone  JS Creeping eruption: a review of clinical presentation and management of 60 cases presenting to a tropical disease unit. Arch Dermatol. 1993;129588- 591
Link to Article
Ogunbanjo  BOEdungbola  LD Outbreak of cutaneous larva migrans in a family household. Trop Geogr Med. 1989;4166- 68
Chaudry  AZLongworth  DL Cutaneous manifestations of intestinal helminthic infections. Dermatol Clin. 1989;7275- 290
Kahn  GJohnson  JA Serum IgE levels in cutaneous larva migrans. J Dermatol. 1971;10201- 203
Harland  PSMeakins  RHHarland  RH Treatment of cutaneous larva migrans with local thiabendazole. BMJ. 1977;2772
Link to Article
Orihuela  ARTorres  JR Single dose of albendazole in the treatment of cutaneous larva migrans. Arch Dermatol. 1990;126398- 399
Link to Article
Caumes  ECarriere  JPatry  AGaxotti  PDanis  MGentilini  M A randomized trial of ivermectin versus albendazole for the treatment of cutaneous larva migrans. Am J Trop Med Hyg. 1993;45641- 644

Correspondence

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles
[Cutaneous larva migrans]. Hautarzt 2008;59(8):622-6.